Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 26;4(1):128-31.
doi: 10.1021/ml300362a. eCollection 2013 Jan 10.

Synthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives

Matshawandile Tukulula  1 , Rajni-Kant Sharma  1 , Maïa Meurillon  1 , Aman Mahajan  1 , Krupa Naran  2 , Digby Warner  2 , Jianxing Huang  3 , Belew Mekonnen  3 , Kelly Chibale  4
Affiliations

Synthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives

Matshawandile Tukulula et al. ACS Med Chem Lett. .

Abstract

The synthesis and antiplasmodial and antimycobacterial evaluation of two new series of nitroimidazole and nitroimidazooxazine derivatives is described. The majority of these compounds, especially hybrids 9d, 9f, and 14b, exhibited potent activity against the chloroquine-resistant K1 strain of Plasmodium falciparum. Furthermore, a notable number from the tetrazole series were significantly more active against M. tuberculosis than kanamycin, a standard TB drug.

Keywords: Nitroimidazoles; antimycobacterial activity; antiplasmodial; nitroimidazooxazines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of lead TB compounds in clinical development.
Scheme 1
Scheme 1
Figure 2
Figure 2
Structures and yields of MCR intermediates and target compounds.
Scheme 2
Scheme 2
See this image and copyright information in PMC

References

    1. WHO report, Global Tuberculosis Control (2011); http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf (Last accessed 23.08.2012).
    1. Koul A.; Arnoult E.; Lounis N.; Guillemont J.; Andries K. The challenge of new drug discovery for tuberculosis. Nature Res. Rev. 2011, 469, 483–490. - PubMed
    1. Marriner G. A.; Nayyar A.; Uh E.; Wong S. Y.; Mukherjee T.; Via L. E.; Carroll M.; Edwards R. L.; Grubber T. D.; Choi I.; Lee J.; Arora K.; England K. D.; Boshoff H. I. M.; Barry C. E. III. The medicinal chemistry of tuberculosis chemotherapy. Top. Med. Chem. 2011, 7, 47–124.
    1. Burrows J. N.; Chibale K.; Wells T. N. C. The state of the art in antimalarial drug discovery and development. Curr. Top. Med. Chem. 2011, 11, 1226–1254. - PubMed
    1. Johnson R.; Streicher E. M.; Louw G. E.; Warren R. M.; van Helden P. D.; Victor T. C. Drug resistance in Mycobacterium tuberculosis. Curr. Issue Mol. Biol. 2006, 8, 97–111. - PubMed